Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer

Paula I. Gonzalez-Ericsson, MD\textsuperscript{1*}, Julia D. Wulfkuhle, PhD\textsuperscript{5*}, Rosa I. Gallagher, PhD\textsuperscript{5}, Xiaopeng Sun, BS\textsuperscript{2}, Margaret L. Axelrod BS\textsuperscript{2}, Quanhu Sheng, PhD\textsuperscript{4}, Na Luo, PhD\textsuperscript{7}, Henry L. Gomez, MD\textsuperscript{6}, Violeta Sanchez, MS\textsuperscript{1}, Melinda E. Sanders, MD\textsuperscript{1,3}, Lajos Pusztai, MD, PhD\textsuperscript{8}, Emanuel Petricoin, PhD\textsuperscript{5}, Kim R.M. Blenman, PhD, MS\textsuperscript{8}, Justin M. Balko, PharmD, PhD\textsuperscript{1,2,3} and the I-SPY2 Trial Team (listed in Collaborators)

Affiliations
Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center\textsuperscript{1}, Departments of Medicine\textsuperscript{2}, Pathology, Microbiology & Immunology\textsuperscript{3}, and Biostatistics\textsuperscript{4}, Vanderbilt University Medical Center, Nashville, TN 37232

Center for Applied Proteomics and Molecular Medicine\textsuperscript{5}, George Mason University, Manassas VA 20110

Department of Medical Oncology\textsuperscript{6}, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú

Department of Anatomy and Histology\textsuperscript{7}, School of Medicine, Nankai University, Tianjin, China

Department of Internal Medicine, Section of Medical Oncology\textsuperscript{8}, Yale Cancer Center, Yale University, New Haven, CT 06511

*These authors contributed equally to this work

Corresponding authors
Kim RM Blenman, PhD, MS
Yale University School of Medicine
300 George Street, Suite 120
New Haven, CT 06511
E-mail: kim.blenman@yale.edu

Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
2200 Pierce Ave., 777 PRB
Nashville, TN 37232-6307
E-mail: justin.balko@vumc.org

Keywords: major histocompatibility-II, biomarker, immunotherapy, breast cancer, neoadjuvant chemotherapy
Abstract

**Purpose:** Immunotherapies targeting PD-1/L1 enhance pathologic complete response (pCR) rates when added to standard neoadjuvant chemotherapy (NAC) regimens in early-stage triple-negative, and possibly high-risk estrogen receptor-positive breast cancer. However, immunotherapy has been associated with significant toxicity and most patients treated with NAC do not require immunotherapy to achieve pCR. Biomarkers discerning patients benefitting from the addition of immunotherapy from those who would achieve pCR to NAC alone are clearly needed. In this study, we tested the ability of MHC-II expression on tumor cells, to predict immunotherapy-specific benefit in the neoadjuvant breast cancer setting.

**Patients and methods:** This was a retrospective tissue-based analysis of three cohorts of patients with breast cancer: 1) primary non-immunotherapy-treated breast cancers (n=381); 2) TNBCs treated with durvalumab and standard NAC (n=48); and 3) HER2-negative patients treated with standard NAC (n=87) or NAC and pembrolizumab (n=66).

**Results:** HLA-DR positivity on ≥5% of tumor cells, defined a priori, was observed in 10% and 15% of primary non-immunotherapy-treated HR+ and triple-negative breast cancers, respectively. Quantitative assessment of MHC-II on tumor cells was predictive of durvalumab + NAC and pembrolizumab + NAC (receiver-operator characteristic [ROC] AUC 0.71; p=0.01 and AUC 0.73; p=0.001, respectively), but not NAC alone (AUC 0.5; p=0.99).

**Conclusions:** Tumor-specific MHC-II has strong candidacy as a specific biomarker of anti-PD-1/L1 immunotherapy benefit when added to standard NAC in HER2-negative breast cancer. Combined with previous studies in melanoma, MHCII has the potential to be a pan-cancer biomarker. Validation is warranted in existing and future Phase II/III clinical trials in this setting.
Translational relevance

Immunotherapies targeting the PD-1/L1 axis benefit a fraction of patients with breast cancer and predictive biomarkers identifying these patients are lacking. Using two orthogonal detection approaches in two early-phase clinical trials, we demonstrate MHC-II expression on tumor cells is a clinical predictor of anti-PD-1/L1 benefit in the neoadjuvant setting.
Introduction

Addition of immune checkpoint drugs targeting the PD-1/L1 axis to chemotherapy provides clinical benefit in breast cancer (BC) patients in the metastatic(1) and neoadjuvant(2) settings. Based on IMPassion130(1) and KEYNOTE-355(3), atezolizumab or pembrolizumab in combination with chemotherapy is now standard of care for locally advanced/metastatic PD-L1+ triple negative breast cancer (TNBC). The addition of PD-1/L1 inhibitors also show varying levels of benefit in patients with metastatic(4, 5) and early stage high-risk(6) hormone receptor positive (HR+) HER2- BC in phase Ib/II trials. Nonetheless, these agents do not benefit all patients, can cause severe and permanent toxicities and come at a high financial cost. Thus, a priori identification of patients likely to benefit from anti-PD-1/L1 is needed. The most assessed biomarkers for immunotherapy outcome prediction in breast cancer are PD-L1 expression and stromal tumor infiltrating lymphocytes (sTILs).

Immunohistochemistry (IHC)-based detection of PD-L1 expression on immune cells is the current companion diagnostic test for treatment with atezolizumab or pembrolizumab in advanced TNBC. However, the two PD-L1 assays approved as companion diagnostics in the US show different positive rates due to differences in staining patterns and scoring systems(7). Additionally, concerns have been raised about inter-pathologist reproducibility for PD-L1 scoring on immune cells(8). In the neoadjuvant setting, increased pathologic complete response (pCR) was observed in both PD-L1 positive and negative groups in the randomized controlled phase III trials KEYNOTE-522(2) and IMPassion031(9). Moreover, PD-L1 expression is not specific to immunotherapy in that it also predicts response to chemotherapy alone, complicating its usage to specifically define patients who require immunotherapy to achieve pCR(10).

Likewise, sTILs have been associated with response to PD-1/L1 inhibitors plus neoadjuvant chemotherapy (NAC) in published correlative studies(11). Assessed in a
standardized manner, sTILs are a robust and reproducible biomarker(12), but strongly predict chemotherapy benefit in the neoadjuvant(13) and adjuvant settings(14). Moreover, sTILs were predictive of pCR in the durvalumab+NAC and NAC alone arms of the GeparNuevo study(10), complicating usage of this marker as a specific biomarker of immunotherapy benefit, like PD-L1. Thus, an optimal biomarker in this setting is one that specifically identifies patients who require the addition of immunotherapy to NAC to achieve pCR, while not identifying patients who have high pCR rates to chemotherapy alone.

MHC-II expression on tumor cells is a predictive biomarker to single-agent anti-PD-1 therapy in melanoma(15) and is also associated with response in Hodgkin’s lymphoma(16). Based on those results, and that the association of MHC-II expression with NAC response has not been studied yet, we evaluated the ability of MHC-II expression to predict the benefit of adding immunotherapy to NAC in BC. We evaluated pCR rates as a primary outcome measure and secondarily as event-free survival (EFS).

Methods

Study approval and patient tissues.

Primary non-immunotherapy-treated breast cancers: Human BC tissue microarrays were constructed from clinical surgical specimens collected at Vanderbilt University Medical Center in Nashville, and Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru under institutionally approved protocols (IRB030747, IRB130916, INEN 10-018). All patients signed written informed consent prior to participation. Eight TMAs were built with one to three 1 mm tumor cores per surgical specimen. Tumors were identified as TNBC or HR+ by IHC for ER, PR, and HER2 performed in a CLIA-approved laboratory. CK/HLA-DR multiplex immunofluorescence (mIF) was performed on 8 TMAs, containing a total of 144 Stage I-III TNBC, of which 90 had received prior NAC, and 237 Stage I-IV HR+/HER2- BC, 9 of which had received prior NAC and 121 who had received letrozole for 10-21 days prior to surgery.
Standard NAC + durvalumab cohort: NCT02489448 was an interventional single-arm Phase I/II clinical trial in newly diagnosed histologically confirmed stage I-III TNBC. Further details of the clinical trial including a patient eligibility and a patients characteristics table have been previously published(17). Participants received nab-paclitaxel 100mg/m2 given weekly for 12 weeks, followed by doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2, given every other week from 13 to 19 weeks as standard care for all patients. Seven patients were included in the Phase I part of the study, four at 3 mg/kg and three at 10 mg/kg dose. The patients in the Phase II part of the study were dosed at 10 mg/kg. Durvalumab was given every two weeks up until 20 weeks, at which point patients underwent surgery within 4 weeks of completion of treatment. Ethical approval was obtained from the Yale Human Investigations Committee (Yale University, HIC# 1409014537) in accordance with the Declaration of Helsinki. The study was approved and was annually reviewed by the internal institutional review board and all patients signed written informed consent prior to participation.

Residual cancer burden (RCB) was evaluated by a pathologist on surgical samples. CK/HLA-DR mIF was performed on 48 out of 57 formalin-fixed paraffin-embedded (FFPE) tissue sections pretreatment biopsy samples stored at -20°C, with loss of sample size due primarily to lack of tissue content in the biopsy sections. CONSORT diagram: Supplementary Figure 1A.

Standard NAC +/- pembrolizumab cohort: The I-SPY2 study is an adaptively randomized phase 2 multicenter trial for stage II/III BC with high risk of recurrence (NCT01042379) evaluating multiple investigational arms in parallel, each consisting of standard NACT (serving as the common control arm) plus an investigational agent/combination. HR, ERBB2-receptor and MammaPrint status performed at baseline are used to classify patients for adaptive randomization. Only ERBB2-negative patients were eligible for randomization to the pembrolizumab arm. Participants in the control arm received standard NAC consisting of 80 mg/m2 intravenous paclitaxel weekly for 12 weeks, followed by 4 cycles of 60 mg/m2 doxorubicin with 600 mg/m2 intravenous cyclophosphamide every 2 to 3 weeks (AC).
Those participants in the pembrolizumab arm received standard NAC as above, with the addition of 200 mg intravenous pembrolizumab every 3 weeks for 4 cycles (weeks 1, 4, 7, and 10) concurrently with paclitaxel. EFS follow-up was up to 1946 days. All participating sites received institutional review board approval, and patients provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki. The I-SPY2 DSMB meets monthly to review patient safety and study progress. RCB was evaluated by a pathologist on surgical samples. Further details of this trial have been published elsewhere(6, 18). Laser capture microdissection (LCM) and reverse-phase protein microarray (RPPA) were performed on fresh frozen tissue biopsies stored at -80°C from the T0 pretreatment (baseline) timepoint from both control (NAC; n=89) and pembrolizumab-treated (NAC+P; n=67) arms. Analysis was performed for the whole cohort and according to HR status. CONSORT diagram:

**Supplementary Figure 1B.**

*Multiplexed immunofluorescence.* Formalin-fixed paraffin-embedded (FFPE) tissue sections were cut at 4 μm and deparaffinized. Antigen retrieval was performed with citrate buffer pH 6. Endogenous peroxidase were blocked and protein block was applied. Sections were then incubated with the primary antibody (HLA-DR TAL1B5 Santa Cruz at 1:4000, panCK AE1/AE3 Biocare at 1:400, HLA-DR/DP/DQ/DX sc-53302 at 1:2000) overnight at 4°C. Sections were then incubated with the secondary antibody and TSA reagent (Tyramide Superboost Kit cat#B40912, Invitrogen) applied according to manufacturer’s recommendations. The procedure was repeated one or two more times with the subsequent different primary antibodies and then counterstained with DAPI for nuclei identification. Tonsil was used as a positive control. A detailed protocol can be found in supplementary data.

*Image analysis and quantification.* Whole slide images were digitally acquired using an AxioScan Z1 slide scanner (Carl Zeiss) at 20x. Automated quantitative scoring was performed by a pathologist blinded to sample characteristics, using QuPath software v0.2.0. A CK mask
was defined with the pixel classifier to outline tumor and non-tumoral compartments. Out of focus areas, tissue folds, necrosis, normal breast and in situ carcinoma were excluded from the analysis. For cases with patchy or null CK expression, tumor areas were manually annotated. Cell segmentation was determined on DAPI. Object classifiers were trained for HLA-DR and HLA-DR/DP/DQ/DX. Each core was visually assessed for correct performance of the quantification algorithm. HLA-DR expression on tumor cells was considered as ≥5% of tumor cells based on prior experience in melanoma (15).

**Laser capture microdissection and reverse-phase protein microarray.** Enriched epithelial cell subpopulations were isolated from 8μm cryosections (>95% purity) using an Arcturus Pixcell Ile LCM system (Arcturus, Mountain View, CA, USA). Resultant cell lysates were printed in in triplicate spots (approx. 10nL per spot) onto nitrocellulose coated slides (Grace Biolabs, Bend, OR, USA) using an Aushon 2470 Arrayer (Aushon Biosystems, Billerica, MA, USA) as described (19). Antibodies used on the arrays were extensively validated before use and are listed in **Supplementary Table 1**. RPPA immunostaining was performed as previously described(20).

For the calibration study, twenty breast cancers with varying degrees of known HLA-DR or HLA-DR/DP/DQ/DX expression from the non-immunotherapy treated tissue microarray cohort were analyzed by identical methods to the above and a linear correlation was established against mIF percent positivity, yielding a cut point of 17,000 units comparable to 5% tumor cell positivity.

**Statistics.** The statistical analyses included herein were not pre-planned per study protocols but were pre-planned per individual requests for existing tissues as secondary or exploratory correlative endpoints. Statistical analyses were performed in R or Graphpad Prism. For RPPA analysis, nominal p-values were calculated using a two-sided T test, and then an adjusted p-value (q-value) was calculated (Benjamini-Hochberg). For 2-group quantitative comparisons, a one-sided T test was used in cases where a specific directionality of change was hypothesized.
based on previous data on melanoma. For response prediction based on defined biomarker subgroups, a one-sided chi-squared ($\chi^2$) test was used. To test interaction effects, a logistic regression model was used to test the interaction between MHC-II status and treatment arm on response (pCR rate) and survival, after adjusting for the main effects. Receiver-operator characteristic (ROC) analysis was performed in Graphpad Prism to evaluate the overall response prediction performance of MHC-II expression across multiple cut points beyond the predefined 5%. Kaplan–Meier and log-rank tests were calculated with a cut point chosen based on the calibration study. Graphs show mean values +/- SEM. P-value cut-offs displayed on plots correspond to “ns” - p>0.05, * p<0.05, ** p<0.01, *** p<0.001, and **** p<0.0001.

Results

**MHC-II is expressed in a subgroup of primary TNBC and HR+ breast cancers.**

Twenty percent of all BCs from the primary non-immunotherapy-treated breast cancers expressed ≥1% HLA-DR in tumor cells by mIF (Supplementary Figure 2 and Supplementary Table 2). Using a pre-defined cut-off of 5% tumor cell positivity that predicted benefit to single-agent anti-PD-1 in melanoma(15), 12% of all BCs assessed expressed ≥5% HLA-DR. Fifteen percent of TNBC showed ≥5% HLA-DR compared to 10% of HR+ tumors. Six percent of treatment naïve TNBC and HR+ patients expressed ≥5% HLA-DR. Twenty-one percent of TNBC patients who received neoadjuvant chemotherapy had ≥5% HLA-DR. Tumor-specific HLA-DR expression was not associated with sTILs (spearman’s $r=0$; p=0.87; n=292 accessible pairs), a common predictive marker for response to NAC alone.

**Tumor specific MHC-II is associated with pCR to durvalumab + NAC.** Fifteen percent of patients from the standard NAC + durvalumab cohort (Figure 1A) showed ≥5% HLA-DR expression on tumor cells. ROC analysis yielded an AUC of 0.71 (p=0.01; Figure 1B). The predefined cut point of 5% resulted in 33% sensitivity, 89% specificity, 67% positive predictive value (PPV) and 64% negative predictive value (NPV). Patients with ≥5% HLA-DR+ tumor cells
demonstrated higher pCR rates (67% versus 36%; one-sided $\chi^2$ p=0.046, Figure 1C and Table 1). HLA-DR expression on non-tumor cells was not predictive of response (Supplementary Figure 3A-C).

Eighty-nine percent of tumors expressing $\geq$5% HLA-DR were also PD-L1+, defined as PD-L1 (Ventana SP263) expression in $\geq$1% on immune or tumor cells and previously reported in Foldi et al (17) (Supplementary Figure 3D). Interestingly, the one patient with a PD-L1-negative HLA-DR $\geq$5% tumor had a pCR (Supplementary Figure 3E).

High tumor-specific MHC-II expression is associated with pembrolizumab benefit. As many markers of anti-tumor immunity are associated with pCR to NAC, a control arm of NAC alone is required to establish predictive capacity for anti-PD-1/L1 benefit. Using existing data from the control (NAC) and pembrolizumab arms of the I-SPY2 TRIAL in high-risk HER2-negative patients (Figure 2A)(6) we tested the association of tumor MHC-II expression with pCR by Reverse Phase Protein Array (RPPA). The RPPA panel utilized was part of a planned correlative analysis and contained 32 protein-based biomarkers, including MHC-II (HLA-DR and pan-MHC-II; HLA-DR/DP/DQ/DX).

Multiple protein markers were quantitatively higher in patients achieving pCR at a nominal (uncorrected) p-value in each of the subgroups tested (all patients, HR+/HER2-, and TNBC), including known correlates of NAC outcome, such as PD-L1 (SP142) and CD3 epsilon, in the control NAC arm for high-risk HR+ and all patients (Supplementary Figure 4). Only pan MHC-II was significantly higher in patients achieving pCR after correcting for multiple comparisons across all patients and high-risk HR+ subgroup (Figure 2B and Supplementary Figures 4 and 5A-B). ROC analysis was performed, yielding an AUC of 0.5 (p=0.99; Figure 2C) in the NAC-alone arm and an AUC of 0.73 (p=0.001; Figure 2D) in the pembrolizumab arm. Since the RPPA analysis did not have a prior-defined cut point for pCR prediction, a calibration study was performed including 20 breast tumors with known MHC-II immunofluorescence status by
performing RPPA analysis for pan-MHC-II on serial sections (r=0.5429; p=0.0134) yielded a comparable cut point of 17,000 normalized units, representing ~5% tumor cell positivity by mIF. This cut point yielded 95% specificity, 38% sensitivity, 80% PPV and 67% NPV (Figure 2D), which was also comparable to that identified in the durvalumab study (Figure 1B). Application of this cut point demonstrated predictive capacity in all pembrolizumab-treated patients and in the HR+ subgroups (one-tailed chi-squared test p=0.0002 and p<0.0001, respectively), but was not predictive of pCR in the control arm (NAC-alone) (Table 2 and Figure 2B). Moreover, testing the interaction between MHC-II status and treatment arm on pCR demonstrated a significant interaction term (p=0.05; Figure 2E). While some clinical and tumor characteristic showed an association with pCR, only pan-MHC-II remained significant on multivariate analysis (Supplementary Table 3).

Tumor-specific MHC-II expression is associated with improved survival in high-risk HER2-negative patients with the addition of anti-PD-1 inhibition to NAC, but not with NAC alone.

Patients with pan-MHC-II-positive tumors who received neoadjuvant pembrolizumab had an improved EFS over those patients with MHC-II-negative tumors (p= 0.079 Figure 3A). However, the same trend was not observed in the NAC alone arm (p=0.22 Figure 3B). Comparing only patients with MHC-II-positive tumors across treatment arms showed that this population had improved EFS when treated with pembrolizumab versus standard NAC alone (p=0.042 Figure 3C). Interestingly, a trend toward worse outcomes was observed for the addition of pembrolizumab in patients with MHC-II-negative tumors (p=0.063 Figure 3D). Cox proportional hazard ratio analyses including clinical and tumor characteristics showed that only pan-MHC-II was significantly associated with survival (Supplementary Table 4).

Discussion

Although immunotherapies targeting the PD-1/L1 axis appear to provide benefit in combination with NAC in some patients, not all patients require these agents to achieve pCR.
Moreover, these agents are not without toxicity. Thus, biomarker approaches to prioritize patients likely to derive benefit from immunotherapy in the neoadjuvant setting are clearly needed. TILs and PD-L1 expression cannot adequately define patients who need additional PD-1/L1 targeted therapy on top of chemotherapy, or at the least, use of such a biomarker would be complicated given that these biomarkers paradoxically define the patients who respond to NAC alone with the highest rates.

The factors driving tumor cell-specific MHC-II expression are not entirely clear, although it’s expression can be driven by inflammatory signals, such as interferons in the tumor microenvironment. Interestingly, there are two variations on this theme that extend the importance of MHC-II expression beyond simply being an interferon-responsive marker. First, there are a wide variety of tumor cell lines that will not upregulate MHC-II with interferon treatment, but will upregulate PD-L1, suggesting an intact interferon-driven JAK STAT signaling pathway(15). Thus, many tumors may lose the ability to express MHC-II, which is thought to be an epigenetic event(21). Second, many cell lines constitutively express MHC-II without interferon stimulation. We hypothesize that this occurs due to innate inflammatory signaling resulting from DNA and RNA-sensing pathways. Overall, the mechanisms and functionality of tumor-specific MHC-II are intriguing and an important subject of study and have recently been reviewed elsewhere(22).

In this study, we demonstrate that tumor epithelium expressed MHC-II protein has the potential to be a *bona fide* predictive biomarker for immunotherapy benefit in high-risk HR+ and TNBCs when added to standard NAC regimens and was not associated with pCR to NAC alone. The pre-defined cut point of 5% used in melanoma proved to be useful for breast cancer in the neoadjuvant setting. In the KEYNOTE-522 study, the addition of pembrolizumab to NAC yielded an improvement in pCR rate from 54.9% to 68.9%, or a 14% change, while in the IMPassion031 trial, the addition of atezolizumab improved pCR rates from 41% to 58%, or a
17% change. Thus, in a biomarker assessment of immunotherapy benefit in a single-arm trial, approximately 20-30% of responding patients should be identified by the biomarker (sensitivity), while most biomarker-negative patients should be predicted to have RD (specificity). The 5% cut point approximated these sensitivity and specificity values.

We found pan-MHC-II to be an independent specific predictor of response and event free-survival to the addition of PD-1/PD-L1 inhibitor to standard NAC. A previous publication on the standard NAC + durvalumab cohort showed that age (OR 1.00 [0.96-1.04] p=0.94), stage (T1 vs T2 0.47[0.15-1.44] p=0.19 and N- vs N+ 1.38 [0.49-4.00] p=0.54) , PD-L1 (≥1% vs <1% 2.63 [0.82-9.21] p=0.11) and TILs (0.99 [0.98-1.01] p=0.56) were not predictive of pCR in univariate analysis(17). Additionally, PD-L1 was not associated with response to the addition of pembrolizumab in high-risk HR+ and TNBC subpopulations, while showing an association with pCR in the HR+ control (NAC alone) arm. Moreover, while the majority of patients with ≥5% HLA-DR+ tumor represent a subset of PD-L1+ (≥1%) tumors, HLA-DR also captured PD-L1- patients that responded to immunotherapy and standard chemotherapy combination.

There are clear limitations to the present study. The sample sizes in both studies contained <100 patients per arm, and there was no control arm in the durvalumab trial. Moreover, the data should be interpreted with caution due to the retrospective nature of the analyses. The use of two assays (mIF and RPPA) could be considered both a strength (e.g. rigor in two methods of assessing MHC-II expression demonstrate similar findings) and a limitation (e.g. the two trial results cannot be directly compared to one another). Importantly, we ensured that the RPPA cut point was calibrated to mIF in order to approximate the 5% cut point. Application of the cut points, at 5% positive tumor cells (immunohistochemical approaches) or 17,000 normalized units (RPPA approach), must be validated in a large randomized controlled trial to confirm these results. Where possible, REMARK guidelines were adhered to with
exceptions primarily related to the retrospective (not pre-planned per the study protocols) nature of the analysis.

Nonetheless, to our knowledge, this is the first study to evaluate and demonstrate the predictive capacity of tumor MHC-II for immunotherapy benefit in patients with breast cancer. The utility of tumor-specific MHC-II was verified by two independent approaches, in two trials comprising different populations of patients, slightly different NAC regimens, and antibodies (anti-PD-1; anti-PD-L1) targeting different sides of the anti-PD-1/L1 axis. These data suggest that tumor-specific MHC-II is an important, potentially pan-cancer, biomarker, which can be measured easily by tissue analyses, including standard IHC, that should be included in correlative analyses in future breast cancer immunotherapy Phase II and III trials.

Conflict-of-interest Statement


Research Support: JMB: Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation. LP: Seattle Genetics, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb.

Patents, Royalties, Other Intellectual Property: EFP: National Institutes of Health patents licensing fee distribution/royalty on RPPA technology. EFP and JW: Co-inventors on filed George Mason University–assigned patents related to RPPA technology and as such can receive royalties and licensing distribution on any licensed IP. JMB: is an inventor on a VUMC-assigned patent regarding immunotherapy biomarkers in cancer, including MHC-II/HLA-DR.

Author contributions

JMB conceived and designed the study. PIGE, JDW, RIG, XS, MLA, QS, NL, VS, LP, EP, KRMB acquired data. PIGE, JDW, RIG, LP, EP, KRMB and JMB analyzed data. HLG, MES, LP,
EP, KRMB provided patient samples. PIGE and JMB wrote the manuscript, which all authors reviewed and edited.

Collaborators

Acknowledgements

Funding for this work was provided by Susan G. Komen Career Catalyst Grant CCRCR18552647 (JMB), NIH/NCI SPORE 2P50CA098131-17 (JMB), Department of Defense Era of Hope Award BC170037 (JMB), and the Vanderbilt-Ingram Cancer Center Support Grant P30 CA68485. Additional funding was provided by NIH T32GM007347 (MLA) and F30CA236157 (MLA). The I-SPY 2 TRIAL and RPPA work was supported by the Gateway for Cancer Research (Grant No. G-16-900); QuantumLeap Healthcare Collaborative; Foundation for the National Institutes of Health; National Cancer Institute Center for Biomedical Informatics and Information Technology (Grant No. 28XS197); a Sta Op Tegen Kanker International Translational Cancer Research Grant; Safeway Foundation; the Bill Bowes Foundation; Quintiles Transnational; Johnson & Johnson; Genentech, Amgen, the San Francisco Foundation; Give Breast Cancer the Boot; Eli Lilly, Pfizer; Eisai; the Harlan family; the Avon Foundation for Women; and Alexandria Real Estate Equities. The Medimmune Durvalumab trial was partly supported by Astra Zeneca and grants from the National Cancer Institute (R01CA219647), the Breast Cancer Research Foundation a Susan Komen Foundation Leadership Grant (SAC 160076) and an annual Investigator Award from the Breast Cancer Research Foundation to. L.P

References


Tables

Table 1: Association of tumor-specific MHC-II/HLA-DR expression with outcome to durvalumab and neoadjuvant chemotherapy

<table>
<thead>
<tr>
<th>RCB</th>
<th>pCR (0)</th>
<th>I</th>
<th>II</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Total (n=48)</td>
<td>20 (42%)</td>
<td>6 (13%)</td>
<td>16 (33%)</td>
<td>6 (13%)</td>
</tr>
<tr>
<td>HLA-DR ≥ 5% (n=9)</td>
<td>6 (67%)</td>
<td>1 (11%)</td>
<td>1 (11%)</td>
<td>1 (11%)</td>
</tr>
<tr>
<td>HLA-DR &lt; 5% (n=39)</td>
<td>14 (36%)</td>
<td>5 (13%)</td>
<td>15 (38%)</td>
<td>5 (13%)</td>
</tr>
</tbody>
</table>

χ² p-value (1-tailed): pCR vs RD: p=0.046 RCB 0/I vs II/III: p=0.057 I

Odds ratio for response (95% CI): 3.57 (0.87 to 14.23) 3.68 (0.81 to 18.81)

Table 2: Association of tumor-specific MHC-II/HLA-DR expression with outcome to pembrolizumab and neoadjuvant chemotherapy or chemotherapy alone

<table>
<thead>
<tr>
<th>HLA-DR/DP/DQ/DX intensity units:</th>
<th>pCR (≥17,000 [RPPA-high] n (%))</th>
<th>&lt;17,000 [RPPA-low] n (%)</th>
<th>RD (≥17,000 [RPPA-high] n (%))</th>
<th>&lt;17,000 [RPPA-low] n (%)</th>
<th>OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>Paclitaxel (n=87)</td>
<td>2 (2%)</td>
<td>11 (13%)</td>
<td>2 (2%)</td>
<td>11 (13%)</td>
</tr>
<tr>
<td>HR+/HER2-</td>
<td>Paclitaxel + pembrolizumab (n=66)</td>
<td>12 (18%)</td>
<td>17 (26%)</td>
<td>3 (2%)</td>
<td>34 (55%)</td>
</tr>
<tr>
<td>TNBC</td>
<td>Paclitaxel (n=38)</td>
<td>2 (4%)</td>
<td>5 (10%)</td>
<td>7 (14%)</td>
<td>35 (71%)</td>
</tr>
<tr>
<td>TNBC</td>
<td>Paclitaxel + pembrolizumab (n=40)</td>
<td>8 (20%)</td>
<td>4 (10%)</td>
<td>2 (5%)</td>
<td>26 (65%)</td>
</tr>
<tr>
<td>TNBC</td>
<td>Paclitaxel + pembrolizumab (n=26)</td>
<td>0 (0%)</td>
<td>6 (16%)</td>
<td>5 (13%)</td>
<td>27 (71%)</td>
</tr>
</tbody>
</table>

Figure Legends

Figure 1: Tumor-specific MHC-II expression is associated with pathologic complete response to NAC and anti-PD-L1 inhibition. A) NCT02489448 clinical trial schema depicting NAC (paclitaxel in yellow, doxorubicin in purple and cyclophosphamide in green) + durvalumab (blue) single arm B) Receiver-operator characteristic curve for predictive capacity of tumor-specific MHC-II (≥5% tumor cell positivity cut point) on pCR. C) pCR rates by HLA-DR biomarker group; p-value represents the result of a one-sided χ² test.

Figure 2: Tumor-specific MHC-II expression specifically predicts benefit to anti-PD-1 inhibition with NAC in high-risk HER2- patients. A) I-SPY2 clinical trial schema depicting NAC (paclitaxel; T; in yellow, doxorubicin in purple and cyclophosphamide in green) + pembrolizumab (P; blue) arm and NAC only control arm B) HLADR/DP/DQ/DX values by outcome for NAC only and NAC + pembrolizumab arms. The dotted line shows the cut point (17,000 units) chosen based on a calibration study comparing RPPA to a 5% tumor-specific
MHC-II cut-point C) Receiver-operator characteristic curve for predictive capacity of tumor-specific MHC-II on pCR in NAC-alone (T) arm D) Receiver-operator characteristic curve for predictive capacity of tumor-specific MHC-II on pCR in pembrolizumab (T+P) arm E) Interaction plot of biomarker group (stratified at 50,000 units) and treatment arm on pCR rate. P value represents interaction term in a logistic regression model after adjusting for main effects (treatment arm and MHC-II status).

**Figure 3: Tumor-specific MHC-II expression is associated with improved event-free survival in high-risk HER2- patients with the addition of anti-PD-1 inhibition to NAC, but not with NAC alone.** A-D) Kalan-Meier analysis of event-free survival (EFS) for the NAC + pembrolizumab and NAC alone arms of the I-SPY2 trial according to HLADR/DP/DQ/DX expression on tumor cells by RPPA. MHC-II+: tumors expressing ≥17,000 normalized units of pan-MHC-II. MHC-II-: <17,000 normalized units. The 17,000 units cut point was chosen based on a calibration study comparing RPPA to a 5% tumor-specific MHC-II cut point by mIF. p value represents the log-rank test.
Figure 1

A Clinical Stage I-III TNBC

Biopsy → Nab-paclitaxel + durvalumab → AC + durvalumab → Surgery

B

AUC: 0.71
p=0.01

5%; 89% spec; 33% sens

C

p=0.046

67% 36%
Figure 2

A Clinical Stage II-III HER2- breast cancer (high risk)

Biopsy

Paclitaxel (T) +/- pembrolizumab (P) AC

Surgery

B

All HER2-

ER+/HER2-

ER-/HER2-

Interaction plot

pCR rate (%)

T+P

T

p=0.05

MHC-II < 17,000

MHC-II ≥ 17,000

p=0.05

0

50000

100000

150000

200000

250000

HLA-DR/DP/DQ/DX Intensity Value

0

50000

100000

150000

200000

250000

HLA-DR/DP/DQ/DX Intensity Value

ER-/HER2-

NAC NAC+P

RD

pCR

RD

pCR

ER+/HER2-

NAC NAC+P

RD

pCR

RD

pCR

RD

pCR

C

T

AUC: 0.5

p=0.99

D

T+P

AUC: 0.73

p=0.001

E

Interaction plot

p=0.05

MHC-II < 17,000

MHC-II ≥ 17,000

0

20

40

60

80

100

100% - Specificity%

0

20

40

60

80

100

100% - Specificity%

17,000; 95% spec; 38% sens

Research.
Figure 3

A. Taxane+Pembro

<table>
<thead>
<tr>
<th>Strata</th>
<th>MHC-II-</th>
<th>MHC-II+</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHC-II-</td>
<td>49</td>
<td>16</td>
</tr>
<tr>
<td>MHC-II+</td>
<td>46</td>
<td>14</td>
</tr>
</tbody>
</table>

Event-free survival

Time after surgery (years)

Number at risk

0.00  0.25  0.50  0.75  1.00

B. Taxane

<table>
<thead>
<tr>
<th>Strata</th>
<th>MHC-II-</th>
<th>MHC-II+</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHC-II-</td>
<td>72</td>
<td>16</td>
</tr>
<tr>
<td>MHC-II+</td>
<td>70</td>
<td>14</td>
</tr>
</tbody>
</table>

Event-free survival

Time after surgery (years)

Number at risk

0.00  0.25  0.50  0.75  1.00

C. MHC-II+ patients

<table>
<thead>
<tr>
<th>Strata</th>
<th>T</th>
<th>T+P</th>
</tr>
</thead>
<tbody>
<tr>
<td>T</td>
<td>16 14 11 8 2 1</td>
<td></td>
</tr>
<tr>
<td>T+P</td>
<td>16 14 13 2 0 0</td>
<td></td>
</tr>
</tbody>
</table>

Event-free survival

Time after surgery (years)

Number at risk

0.00  0.25  0.50  0.75  1.00

D. MHC-II- patients

<table>
<thead>
<tr>
<th>Strata</th>
<th>T</th>
<th>T+P</th>
</tr>
</thead>
<tbody>
<tr>
<td>T</td>
<td>72 70 59 29 14 1</td>
<td></td>
</tr>
<tr>
<td>T+P</td>
<td>49 46 35 2 0 0</td>
<td></td>
</tr>
</tbody>
</table>

Event-free survival

Time after surgery (years)

Number at risk

0.00  0.25  0.50  0.75  1.00

p = 0.079

p = 0.22

p = 0.042

p = 0.063
Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer

Paula I Gonzalez-Ericsson, Julia D. Wulfkhule, Rosa I Gallagher, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-21-0607

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2021/07/16/1078-0432.CCR-21-0607.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2021/07/22/1078-0432.CCR-21-0607. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.